OC-0253: Bevacizumab with chemoradiation in rectal cancer: clinical and translational results of the AXEBeam trial.

MLA

Verstraete, M., et al. “OC-0253: Bevacizumab with Chemoradiation in Rectal Cancer: Clinical and Translational Results of the AXEBeam Trial.” Radiotherapy & Oncology, vol. 111, Apr. 2014, p. S97. EBSCOhost, https://doi.org/10.1016/S0167-8140(15)30358-3.

APA

Verstraete, M., Debucquoy, A., Dekervel, J., Van Pelt, J., Chiritescu, G., Dumon, K., D’Hoore, A., Sagaert, X., Van Cutsem, E., & Haustermans, K. (2014). OC-0253: Bevacizumab with chemoradiation in rectal cancer: clinical and translational results of the AXEBeam trial. Radiotherapy & Oncology, 111, S97. https://doi.org/10.1016/S0167-8140(15)30358-3

Chicago

Verstraete, M., A. Debucquoy, J. Dekervel, J. Van Pelt, G. Chiritescu, K. Dumon, A. D’Hoore, X. Sagaert, E. Van Cutsem, and K. Haustermans. 2014. “OC-0253: Bevacizumab with Chemoradiation in Rectal Cancer: Clinical and Translational Results of the AXEBeam Trial.” Radiotherapy & Oncology 111 (April): S97. doi:10.1016/S0167-8140(15)30358-3.